SCHEMBL2396564

SCHEMBL2396564

NC(=O)N(S)c1ccc(Cl)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.43
ADRA2A P08913 2/20 0.41
ADRA2B P18089 2/20 0.41
ADRA2C P18825 2/20 0.41
SIRT6 Q8N6T7 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 1/20 0.38
PIK3CD O00329 1/20 0.35
KCNQ3 O43525 4/20 0.35
KCNQ2 O43526 4/20 0.35
KCNE1 P15382 3/20 0.35
KCNQ1 P51787 3/20 0.35
MDM4 O15151 1/20 0.35
TP53 P04637 1/20 0.35
MDM2 Q00987 1/20 0.35
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DGAT1 O75907 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28603487 0.84 NAPRT (0.48) NAPRTADRA2AADRA2BADRA2CALDH1A1
SCHEMBL9563445 0.79 NAPRT (0.43) NAPRTADRA2AADRA2BADRA2CSIRT6
SCHEMBL1889419 0.79 ADRA2A (0.41) ADRA2AADRA2BADRA2CKMT2AKCNQ3
SCHEMBL14053508 0.79 FDFT1 (0.33)
SCHEMBL725811 0.76 MAPT (0.32) ALDH1A1MAPTL3MBTL1POLBTDP1
SCHEMBL526060 0.75 NPC1 (0.42) ALDH1A1LMNAMAPTL3MBTL1SMN1; SMN2
SCHEMBL2397345 0.75 NNMT (0.54) SIRT6ALDH1A1MEN1KMT2ALMNA
SCHEMBL11066001 0.72 PARP1 (0.30)
SCHEMBL28352536 0.70 NAPRT (0.37) NAPRTADRA2AADRA2BADRA2CALDH1A1
SCHEMBL17681657 0.70 NAPRT (0.50) NAPRTADRA2AADRA2BADRA2CALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017608-B2 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2011-09-13 US disclosed
EP-1608647-B1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2006-07-06 US disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors MAP3K13, AKT3, MAP3K3 NAPRT 1502/4885ADRA2A 2915/4885ADRA2B 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.